Study of Biomarkers That Predict the Evolution of Huntington's Disease
Keywords
Abstract
Description
In this context, we propose to focus our research not only on biological and genetic markers but also on neuroimaging and neuropsychological markers using paradigms of time reactions or measurement of evoked potentials. We hope to identify sensitive markers of the degenerative process of Huntington's disease even when patients carrying the gene may or may not have reported the disease.
The project is centered on 2 axes:
1. identification of the genetic polymorphism which may explain the phenotypic variability seeing in Huntington's disease
2. identification of biological, genetic and imaging biomarkers that could be used as predictors of clinical progression of Huntington's disease This research is based on the existence of a well followed and well characterized cohort of patients through the Francophone Huntington Network ("RESEAU HUNTINGTON de LANGUE FRANCAISE", RHLF). Therefore, this will help to combine the clinical and biological expertise of RHLF.
Dates
Last Verified: | 09/30/2014 |
First Submitted: | 06/22/2011 |
Estimated Enrollment Submitted: | 08/04/2011 |
First Posted: | 08/08/2011 |
Last Update Submitted: | 10/07/2014 |
Last Update Posted: | 10/08/2014 |
Actual Study Start Date: | 08/31/2003 |
Estimated Primary Completion Date: | 12/31/2020 |
Estimated Study Completion Date: | 12/31/2020 |
Condition or disease
Intervention/treatment
Other: Patient
Other: Healthy subject
Phase
Arm Groups
Arm | Intervention/treatment |
---|---|
Patient Voluntary Huntington patients symptomatic or asymptomatic, with a number of nucleotide expansion(CAG) ≥36 and who know their genetic status | Other: Patient Neurological, neuropsychological, neuroimaging evaluation and biological sample |
Healthy subject Voluntary controls with no family history of huntington's disease | Other: Healthy subject Neurological, neuropsychological, neuroimaging evaluation and biological sample |
Eligibility Criteria
Ages Eligible for Study | 18 Years To 18 Years |
Sexes Eligible for Study | All |
Sampling method | Non-Probability Sample |
Accepts Healthy Volunteers | Yes |
Criteria | Inclusion Criteria (patient): - Voluntary patients symptomatic or asymptomatic - Patient with a number of CAG ≥36) - Patient who know his genetic status - Age greater than 18 years or equal to 18 years - Patient who provided written informed consent Exclusion Criteria (patient): - Deterioration of the protocol preventing the understanding of the protocol Inclusion Criteria (control): - Voluntary controls with no family history of huntington's disease - Control with a number of CAG <36 - Age greater than 18 years or equal to 18 years - Control who provided written informed consent Exclusion Criteria (control): - Deterioration of the protocol preventing the understanding of the protocol |
Outcome
Primary Outcome Measures
1. Unified Huntington Disease Rating Scale (UHDRS) [up to 9 years]
Secondary Outcome Measures
1. Mattis Dementia Rating Scale [up to 9 years]
2. Trail Making test A et B [up to 9 years]
3. Hopkins Verbal Learning Test [up to 9 years]
4. Categorical Fluency [up to 9 years]
5. Language tests [up to 9 years]
6. Social cognition tests [up to 9 years]
7. Comportment scale [up to 9 years]
8. Neuroimaging [up to 9 years]
9. Neuropsychological evaluation [up to 9 years]
10. Electrophysiological tests [up to 9 years]